Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Incyte Corp., 3 years.
Incyte Corp.
Director
ACADIA Pharmaceuticals Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
ACADIA Pharmaceuticals Inc. May 29, 202685.4%
-
Incyte Corp. June 10, 202598.5%
-
Incyte Corp. June 12, 202499.3%
-
Incyte Corp. June 14, 202398.5%
-
ACADIA Pharmaceuticals Inc. June 1, 202393.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Incyte Corp. | Grant or award | +255 | $113.36 | $28,907 |
| Jun 8, 2026 | Incyte Corp. | Grant or award | +1,642 | — | — |
| May 29, 2026 | ACADIA Pharmaceuticals Inc. | Option exercise | +8,107 | — | — |
| Mar 31, 2026 | Incyte Corp. | Grant or award | +269 | $94.12 | $25,318 |
| Dec 31, 2025 | Incyte Corp. | Grant or award | +245 | $98.77 | $24,199 |
| Sep 30, 2025 | Incyte Corp. | Grant or award | +289 | $84.81 | $24,510 |
| Jun 30, 2025 | Incyte Corp. | Grant or award | +367 | $68.10 | $24,993 |
| Jun 10, 2025 | Incyte Corp. | Grant or award | +2,518 | — | — |
| May 29, 2025 | ACADIA Pharmaceuticals Inc. | Option exercise | +9,387 | — | — |
| Mar 31, 2025 | Incyte Corp. | Grant or award | +363 | $60.55 | $21,980 |
| Dec 31, 2024 | Incyte Corp. | Grant or award | +339 | $69.07 | $23,415 |
| Sep 30, 2024 | Incyte Corp. | Grant or award | +378 | $66.10 | $24,986 |
| Jun 28, 2024 | Incyte Corp. | Grant or award | +409 | $60.62 | $24,794 |
| Jun 12, 2024 | Incyte Corp. | Grant or award | +2,830 | — | — |
| May 29, 2024 | ACADIA Pharmaceuticals Inc. | Option exercise | +6,652 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.